<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Liquidia Technologies, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Liquidia Technologies, Inc.

    Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINTÂŽ particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $166,000,000
    • SIC CODE
      3841
    • NIN CODE
      ####
    • LEADERSHIP
      Neal Fowler
    • FOUNDED
      2004
    • EMPLOYEES
      51-100
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Interpace Diagnostics Group, Inc.

    Interpace Diagnostics Group, Inc.

    Interpace Diagnostics is focused on developing and commercializing molecular diagn...

    Interpace Diagnostics is focused on developing ...

    Filing Type:    PU
    LogicBio Therapeutics, Inc.

    LogicBio Therapeutics, Inc.

    LogicBio is a Cambridge, MA-based genome editing company focused on delivering the...

    LogicBio is a Cambridge, MA-based genome editin...

    Filing Type:    PU
    Fortress Biotech, Inc.

    Fortress Biotech, Inc.

    Fortress Biotech ("Fortress" or "the Company") is an innovative biopharmaceutical ...

    Fortress Biotech ("Fortress" or "the Company") ...

    Filing Type:    PU
    Neon Therapeutics, Inc.

    Neon Therapeutics, Inc.

    Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...

    Neon Therapeutics is a clinical-stage immuno-on...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Ascendis Pharma A/S

    Ascendis Pharma A/S

    Ascendis Pharma is applying its innovative technology platform to build a leading,...

    Ascendis Pharma is applying its innovative tech...

    Filing Type:    PU
    LivaNova PLC

    LivaNova PLC

    LivaNova is a global medical technology company built on decades of experience and...

    LivaNova is a global medical technology company...

    Filing Type:    PU
    AtriCure, Inc.

    AtriCure, Inc.

    As a leading provider of innovative technologies for the treatment of Atrial Fibri...

    As a leading provider of innovative technologie...

    Filing Type:    PU
    Mesoblast Limited

    Mesoblast Limited

    Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...

    Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...

    Filing Type:    PU
    Phoenix PharmaLabs Inc

    Phoenix PharmaLabs Inc

    Phoenix PharmaLabs, Inc. (PPL) is a privately held, pre-clinical stage drug develo...

    Phoenix PharmaLabs, Inc. (PPL) is a privately h...

    Amount Raised:    $1,079,375.00
    Fundraising Status:    EC
    Filing Type:    CF
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Neurocarrus Inc

    Neurocarrus Inc

    Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...

    Neurocarrus is developing a breakthrough therap...

    Amount Raised:    $344,168.00
    Fundraising Status:    EC
    Filing Type:    CF
    ©2026 National Investor Network. All Rights Reserved.